<DOC>
	<DOCNO>NCT00409461</DOCNO>
	<brief_summary>Proof concept study islet transplantation , two treatment arm ( ATG SIR-TAC versus ATG SIR ) consist ten type 1 diabetic patient</brief_summary>
	<brief_title>Comparison Sirolimus Alone With Sirolimus Plus Tacrolimus Type 1 Diabetic Recipients Cultured Islet Cell Grafts</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Type 1 insulindependent diabetic patient Cpeptide &lt; 0.15 nmol/l ( &lt; 0.45 Âµg/l ) 6 min . glucagon IV ( 1mg ) ( glycemia &gt; 180 mg/dl ) diabetic nephropathy hypoglycaemic unawareness smoker transplantation plasma creatinine &gt; 2 mg/dl albuminuria &gt; 1000 mg/24 hr abnormal liver function history thrombosis pulmonary embolism history malignancy , tuberculosis chronic viral hepatitis history serious illness could relevant protocol HLA antibody EBV antibody negative HIV 1 &amp; 2 antibody positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>